ReviewAn overview of current delivery systems in cancer gene therapy
Introduction
Gene therapy has become the research focus for many laboratories in pharmacy, medicine, biochemistry and chemical engineering worldwide. However, the growing potential of gene therapy for both genetically based and infectious diseases will not achieve its goals until the issue of gene delivery has been resolved. During the past 15 years, more than 400 clinical studies in gene therapy have been evaluated; almost 70% of these studies are in the area of cancer gene therapy [1].
The main objective in gene therapy is successful in vivo transfer of the genetic materials to the targeted tissues. The aim from the delivery system varies according to the application. For example, prolonged and sustained expression is needed for treating diseases related to one gene dysfunction like hypercholesterolemia while short period of gene expression is sufficient for most cancer gene therapy strategies.
Due to the complex nature of cancer, many therapeutic genes were utilized to eliminate cancerous lesions. The development of cancer cells is associated with multiple alterations on the genetic level of these cells [2]. Oncogenes and tumor suppressor genes play a crucial role in cancer development. These two gene groups counterbalance each other. While tumor suppressor genes induce apoptosis (programmed cell death), oncogenes enhance cell proliferation. Therefore, apoptotic genes and anti-oncogenes can be efficiently utilized in cancer treatment. On the other hand, chemotherapy and gene therapy can be combined via suicide gene strategy. This strategy relies on the conversion of a non-toxic prodrug into its active cytotoxic metabolite within the cancerous cells. This conversion is mediated by a non-mammalian enzyme, which is over-expressed in the neoplastic cells as a result of a successful transfection with their genes [3], [4]. Cancer is also immunogenic in nature [5]; therefore, boosting the immune response against cancerous cells can be achieved via genes encoding for cytokines such as interleukin-12 (IL-12) gene widely used in cancer gene therapy [6], [7]. Regardless of the therapeutic strategy, the development of efficient and safe gene delivery systems remains the main challenge for gene therapy including its main application—cancer gene therapy.
Despite that naked DNA was used successfully when injected directly into the tumor [6], [8] or as DNA vaccines [9], [10], it is highly prone to tissue clearance and totally inefficient for systematic delivery [11]. Gene therapy vehicles can be categorized into two groups: biological and non-biological systems. Each group has its own advantages and limitations. Biological carries are viruses, which were naturally evolved to infect cells and transfer their genetic materials into the host cells. Both RNA and DNA viruses have been evaluated as possible gene carriers. Viruses used in gene therapy are modified in the laboratory to eliminate their pathogenicity and retain their high efficiency in gene transfer. They are, however, difficult to produce and toxic (in particular immunogenic), as well as having a limitation in terms of the size of the inserted genetic materials [12]. These limitations are less encountered in non-viral gene carriers namely cationic polymers, cationic peptides and cationic lipids (liposomes). Their efficiency, however, is less than that of their viral counterparts. In addition, physical properties such as size and zeta potential play a critical role in their efficiency. In either delivery system, selected modifications that can produce safe, efficient and targetable gene carriers are desirable.
The most commonly used gene delivery systems (viral and non-viral) for cancer treatment and the recent developments in this area are the focus of this article. Emphasis is placed on the structure of cationic liposomes and on the different liposomal-DNA complexes.
Section snippets
Retrovirus
Retrovirus carriers are developed by replacing the vital viral genes with therapeutic ones. The ability of retroviral vectors to successfully deliver foreign genetic materials was first described in 1981 [13], [14]. Retroviruses are small RNA viruses with DNA intermediate, which integrates into the host genome producing the viral proteins (gag, pol and env), which are removed when developing the gene delivery carrier. In a recent study, a retroviral vector was encapsulated with genetic segment
Non-biological gene delivery systems (non-viral vectors)
Non-viral systems are cationic in nature. They interact with negatively charged DNA through electrostatic interactions. The total charge, however, maintains a positive net value. This will enable the carrier of efficiently interacting with the negatively charged cell membranes and internalizes into the cell, which occurs mainly through the endocytosis pathway [70].
Closing remarks
Gene therapy for cancer is the main application of gene therapy. A good gene delivery formulation for cancer therapy should encapsulate and protect the nucleic acid materials, escape the endosomal degradation and specifically target the tumor site. Both viral and non-viral vectors were developed and evaluated for delivering therapeutic genes that can terminate cancer cells. In the past few years, many modifications to the current delivery systems and novel carrier systems have been developed to
Acknowledgements
I would like to thank Mr. Saleh Saleh for providing the drawings of Fig. 2.
References (151)
The molecular biology of cancer
Mol. Aspects Med.
(2000)- et al.
The emerging fields of suicide gene therapy and virotherapy
Trends Mol. Med.
(2002) Metabolic suicide genes in gene therapy
Pharmacol. Ther.
(1994)- et al.
Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12
Hepatology
(2001) - et al.
Introduction to cancer gene therapy
Surg. Oncol. Clin. N. Am.
(2002) - et al.
Formation of infectious progeny virus after insertion of herpes simplex thymidine kinase gene into DNA of an avian retrovirus
Cell
(1981) - et al.
Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs
Pharmacol. Ther.
(1999) - et al.
Development of lentiviral vectors for gene therapy for human diseases
Blood
(2000) - et al.
Gene therapy for prostate cancer: current status and future prospects
J. Urol.
(2001) - et al.
Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model
Mol. Ther.
(2002)